Quick Answer
Definium Therapeutics, Inc. reported Total Assets of $440.10 million for fiscal year 2025.
Definium Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $440.10M | +45.7% |
| 2024 | $302.15M | +142.6% |
| 2023 | $124.54M | -26.7% |
| 2022 | $169.99M | +3.7% |
| 2021 | $164.00M | +101.2% |
| 2020 | $81.52M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $236.92M | -25.9% | -10.6% |
| June 30, 2025 | $265.09M | -1.1% | -3.7% |
| March 31, 2025 | $275.32M | -0.1% | -8.9% |
| December 31, 2024 | $302.15M | +142.6% | -5.5% |
| September 30, 2024 | $319.77M | +125.9% | +19.3% |
| June 30, 2024 | $268.14M | +88.7% | -2.7% |
| March 31, 2024 | $275.53M | +77.2% | +121.2% |
| December 31, 2023 | $124.54M | -26.7% | -12.0% |
- Definium Therapeutics, Inc. showed an increase of +45.7% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Definium Therapeutics, Inc.’s total assets has grown by 439.9% (from $81.52 million to $440.10 million).
- The most recent figure is from Definium Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: